jetcityimage/iStock Editorial via Getty Images
Eli Lilly (NYSE:LLY) shares trended lower in the premarket on Thursday after the Indiana-based drugmaker lowered its full-year non-GAAP earnings outlook to a level below consensus, despite surging sales for its weight loss drugs.
The pharma giant reported $12.7B in revenue